Siegfried Kasper

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 528 publications

In memoriam: Professor Shigeto Yamawaki (January 15, 1954-June 8, 2026)-a visionary leader connecting Japan, Asia, and the world.

In memoriam: Professor Shigeto Yamawaki (January 15, 1954-June 8, 2026)-a visionary leader connecting Japan, Asia, and the world.

Journal: The international journal of neuropsychopharmacology

Published: June 27, 2026

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry.

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: June 23, 2026

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.

Journal: International journal of psychiatry in clinical practice

Published: April 29, 2026

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

Journal: The British journal of psychiatry : the journal of mental science

Published: March 25, 2026

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Journal: ESMO gastrointestinal oncology

Published: March 19, 2026

World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa.

World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa.

Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

Published: March 01, 2026

Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.

Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.

Journal: JAMA network open

Published: February 25, 2026

Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.

Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: February 13, 2026

Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel.

Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: February 06, 2026

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Showing 1-12 of 528

Last Updated: 09/26/2026